Stocktoria
Alector, Inc. ALEC
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-02-07
Alector, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $21.0M | $100.6M | $97.1M | $133.6M | $207.1M |
| R&D expense | $123.1M | $185.9M | $192.1M | $210.4M | $189.4M |
| Operating income | -$156.0M | -$145.0M | -$151.7M | -$137.8M | -$37.4M |
| Income tax | $168,000 | $128,000 | $5.2M | $3.3M | $0 |
| Net income | -$142.9M | -$119.0M | -$130.4M | -$133.3M | -$36.3M |
| EPS (diluted) | $-1.39 | $-1.23 | $-1.56 | $-1.62 | $-0.45 |
| Operating cash flow | -$184.0M | -$229.9M | -$184.2M | -$20.3M | $298.6M |
| Free cash flow | -$184.1M | -$231.2M | -$186.5M | -$24.4M | $295.3M |
| Cash & equivalents | $65.8M | $33.0M | $74.6M | $154.3M | $329.2M |
| Total assets | $293.2M | $468.3M | $621.8M | $787.6M | $814.7M |
| Total liabilities | $262.6M | $341.5M | $487.7M | $573.2M | $513.9M |
| Shareholders' equity | $30.6M | $126.8M | $134.2M | $214.4M | $300.7M |
Source: SEC EDGAR filings · CIK 0001653087 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.